The Senate Health, Education, Labor & Pensions Committee today held the in a series of bipartisan hearings on how to make prescription drugs more affordable, which focused on recent from a National Academies of Sciences, Engineering and Medicine report. In a submitted to the committee in June, AHA urged Congress and the administration to address the rising cost of drugs, and offered specific recommendations to increase competition, innovation and transparency, promote payment for value, improve access and align incentives. In her opening remarks at today鈥檚 hearing, Committee Ranking Member Patty Murray (D-WA) criticized the administration for reducing Medicare payments for hospital outpatient drugs under the 340B drug savings program by nearly 30% effective Jan. 1. 鈥淣ot only will this do absolutely nothing to combat high drug prices, it will result in less funding for safety net providers to provide critical services to low-income and vulnerable patients,鈥 she said. Last month, AHA joined by the Association of American Medical Colleges and America鈥檚 Essential Hospitals filed a to prevent the payment cut.

Related News Articles

Headline
The Trump administration today announced steps drug manufacturers must take to lower prescription drug prices in the U.S. to "most favored nation" pricing, the鈥
Headline
The Department of Health and Human Services today issued a notice announcing a 340B Rebate Model Pilot Program as a voluntary mechanism for qualifying drug鈥
Headline
The Department of Health and Human Services May 20 announced it has identified specific pricing targets for pharmaceutical manufacturers to meet to satisfy鈥
Headline
The Centers for Medicare & Medicaid Services May 12 released draft guidance for the third round of negotiations for the Medicare Drug Price Negotiation鈥
Headline
The White House May 12 released an executive order to reduce prescription drug costs by allowing consumers to make direct purchases from drug manufacturers at鈥
Headline
The White House April 15 released an executive order directing federal agencies to undertake a broad range of tasks aimed at reducing the costs of prescription鈥